Summary:
In adults with type 2 diabetes (n=1,879) from SURPASS-2 Phase 3 trial, once-weekly tirzepatide (5, 10, or 15 mg) for 40 weeks demonstrated significantly greater improvements in beta-cell function (C-peptide, proinsulin) and insulin sensitivity, with superior HbA1c reduction (2.1-2.4% vs 1.9%) and weight loss (11-13 kg vs 9.6 kg) compared to semaglutide 1.0 mg weekly, with consistent benefits regardless of baseline beta-cell function or insulin resistance status.
| PICO | Description |
|---|---|
| Population | Adults with T2D (n=1,879) from 128 sites in 8 countries in SURPASS-2 trial. |
| Intervention | Tirzepatide 5, 10, or 15 mg subcutaneous weekly for 40 weeks. |
| Comparison | Semaglutide 1.0 mg subcutaneous weekly for 40 weeks. |
| Outcome | Greater beta-cell function and insulin sensitivity improvement. HbA1c -2.1-2.4% vs -1.9%. Weight -11-13 kg vs -9.6 kg. |
SURPASS-2
RCT · type 2 diabetes · 40 weeks
Tirzepatide produced greater HbA1c and weight reductions than semaglutide, with larger gains in beta-cell function and insulin sensitivity across all baseline phenotypes.
Clinical Context
Tirzepatide is a dual GIP/GLP-1 agonist that achieved superior outcomes vs semaglutide. This analysis evaluates the mechanistic basis.
Clinical Pearls
1. Dual Agonism Provides Mechanistic Advantage: Greater improvement of both beta-cell function AND insulin sensitivity.
2. Benefits Independent of Baseline Phenotype: Consistent benefits regardless of baseline metabolic status.
3. Fasting Biomarkers Reflect Metabolic Improvement: Greater proinsulin reduction suggests reduced beta-cell stress.
4. Clinical-Mechanistic Correlation: Mechanism explains superior HbA1c and weight outcomes.
Practical Application
Consider tirzepatide when maximal glycemic control and weight reduction are goals. May provide additional benefit for semaglutide non-responders.
Study Limitations
Mechanistic analysis, not primary design. Indirect biomarker measures rather than clamp studies.
Bottom Line
Tirzepatide’s superiority reflects greater improvement in both beta-cell function and insulin sensitivity through dual GIP/GLP-1 agonism.
Source: Frias JP, et al. “Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity (SURPASS-2).” JCEM, 2024. Read article